Dysregulation of tyrosinase activity: a potential link between skin disorders and neurodegeneration.
| Autor: | Jin W; Institute for Molecular Bioscience, The University of Queensland, St. Lucia, QLD, 4072, Australia., Stehbens SJ; Institute for Molecular Bioscience, The University of Queensland, St. Lucia, QLD, 4072, Australia., Barnard RT; School of Chemistry and Molecular Biosciences, The University of Queensland, St. Lucia, QLD, 4072, Australia., Blaskovich MAT; Institute for Molecular Bioscience, The University of Queensland, St. Lucia, QLD, 4072, Australia., Ziora ZM; Institute for Molecular Bioscience, The University of Queensland, St. Lucia, QLD, 4072, Australia. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | The Journal of pharmacy and pharmacology [J Pharm Pharmacol] 2024 Jan 06; Vol. 76 (1), pp. 13-22. |
| DOI: | 10.1093/jpp/rgad107 |
| Abstrakt: | Objectives: The co-occurrence of melanoma and Parkinson's disease (PD) is higher than expected. We review the relationship between melanoma and PD, then proffer a hypothesis of how dysregulated human tyrosinase could be involved in both diseases via the loss of dopamine and neuromelanin-positive neurons in PD and the genesis alterations in melanin content during melanoma. Key Findings: There are a surprising number of links between skin disorders and neurodegenerative diseases. Some risk factors related to the co-occurrence of PD and melanoma have been extensively investigated over the past 15 years. It has been proposed that human tyrosinase, an enzyme participating in the biosynthesis of neuromelanin in the brain and of melanin in the skin, plays a role. Abnormally dysregulated human tyrosinase impacts the genesis and progression of melanoma and PD. Summary: The dual role of human tyrosinase places it as the potential critical link between these seemingly distinct conditions. Detecting and monitoring human tyrosinase activity in the progression of melanoma and PD opens new opportunities for early diagnosis and treatment of both diseases. (© The Author(s) 2023. Published by Oxford University Press on behalf of the Royal Pharmaceutical Society.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|